Generic Price Fixing Probe: First Charges Unsealed, More May Come Before Inauguration Day

Heritage Pharmaceuticals’ former CEO and former president charged by US DOJ with conspiracy to fix prices and allocate customers for doxycycline and glyburide; Heritage alleges they embezzled intellectual property.

United States Department of Justice headquarter building in Washington D.C.

The Department of Justice has filed the first charges in its two-year antitrust investigation of the generic drug industry, charging two former executives at Heritage Pharmaceuticals Inc. with conspiracy to fix prices and allocate customers for the antibiotic doxycycline and the diabetes drug glyburide.

The felony charges against former CEO Jeffrey Glazer and former president Jason Malek were unsealed Dec. 14 in the US...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics